SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Myogen (MYOG) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (22)3/7/2006 9:53:34 AM
From: tuck  Respond to of 50
 
I didn't say I thought it was bad. I just said the deal seemed short of investor expectations. Apparently those were rather high, having been pumped up by Cramer. Do you really think it was the income statement shortfall of a couple million in revenue or the lack of guidance that's causing this ten per cent haircut? Maybe the latter, but I think it's just a sell the news scenario. Whatever, I just sold my puts; my wallet feels much better now.

Despite the news that ENCY has one less partner to dance with, it is currently up a bit on a down morning for Mr. Market. (Disclosure: long ENCY again).

Cheers, Tuck



To: rkrw who wrote (22)3/7/2006 12:20:22 PM
From: tuck  Read Replies (1) | Respond to of 50
 
Actually, funny you should mention buyout . . . for with this deal, the possibility of a near term buyout of MYOG diminishes. Much of the ride here was buyout speculation. Cramer had called for $40 as a target, $50 with a buyout.

Can't say I've heard the rumors about ENCY being bought, was that a YMB speculation?

If I see a certain pattern, I might even trade MYOG long. But not yet.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News